Upstream Bio (UPB) Competitors

$8.79 -0.57 (-6.09%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$9.11 +0.32 (+3.61%)

As of 07:08 AM Eastern

UPB vs. ZYME, GENB, PHVS, CAPR, and TSHA

Should you buy Upstream Bio stock or one of its competitors? MarketBeat compares Upstream Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Upstream Bio include Zymeworks (ZYME), Generate Biomedicines (GENB), Pharvaris (PHVS), Capricor Therapeutics (CAPR), and Taysha Gene Therapies (TSHA). These companies are all part of the "pharmaceutical products" industry.

How does Upstream Bio compare to Zymeworks?

Zymeworks (NASDAQ:ZYME) and Upstream Bio (NASDAQ:UPB) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

Zymeworks has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market.

Zymeworks has higher revenue and earnings than Upstream Bio. Zymeworks is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96M	16.51	-$81.13M	-$1.37	N/A
Upstream Bio	$2.85M	167.84	-$143.44M	-$2.67	N/A

92.9% of Zymeworks shares are held by institutional investors. 33.5% of Zymeworks shares are held by company insiders. Comparatively, 13.6% of Upstream Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Zymeworks had 20 more articles in the media than Upstream Bio. MarketBeat recorded 25 mentions for Zymeworks and 5 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 1.31 beat Zymeworks' score of 0.16 indicating that Upstream Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	2 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Upstream Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Zymeworks currently has a consensus target price of $38.00, suggesting a potential upside of 58.60%. Upstream Bio has a consensus target price of $38.75, suggesting a potential upside of 340.84%. Given Upstream Bio's higher probable upside, analysts plainly believe Upstream Bio is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92
Upstream Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Zymeworks has a net margin of -126.92% compared to Upstream Bio's net margin of -4,718.96%. Zymeworks' return on equity of -37.97% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-126.92%	-37.97%	-25.31%
Upstream Bio	-4,718.96%	-41.73%	-40.35%

Summary

Zymeworks beats Upstream Bio on 12 of the 17 factors compared between the two stocks.

How does Upstream Bio compare to Generate Biomedicines?

Generate Biomedicines (NASDAQ:GENB) and Upstream Bio (NASDAQ:UPB) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

Generate Biomedicines has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Generate Biomedicines' return on equity of 0.00% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Upstream Bio	-4,718.96%	-41.73%	-40.35%

Generate Biomedicines has higher revenue and earnings than Upstream Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$30.30M	65.45	N/A	N/A	N/A
Upstream Bio	$2.85M	167.84	-$143.44M	-$2.67	N/A

In the previous week, Generate Biomedicines had 10 more articles in the media than Upstream Bio. MarketBeat recorded 15 mentions for Generate Biomedicines and 5 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 1.31 beat Generate Biomedicines' score of -0.29 indicating that Upstream Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Upstream Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Generate Biomedicines presently has a consensus target price of $25.40, indicating a potential upside of 64.19%. Upstream Bio has a consensus target price of $38.75, indicating a potential upside of 340.84%. Given Upstream Bio's higher probable upside, analysts clearly believe Upstream Bio is more favorable than Generate Biomedicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Upstream Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Generate Biomedicines beats Upstream Bio on 7 of the 10 factors compared between the two stocks.

How does Upstream Bio compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and Upstream Bio (NASDAQ:UPB) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

Pharvaris has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Upstream Bio's return on equity of -41.73% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Upstream Bio	-4,718.96%	-41.73%	-40.35%

Pharvaris presently has a consensus target price of $49.18, indicating a potential upside of 60.20%. Upstream Bio has a consensus target price of $38.75, indicating a potential upside of 340.84%. Given Upstream Bio's higher probable upside, analysts clearly believe Upstream Bio is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Upstream Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Upstream Bio has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Upstream Bio	$2.85M	167.84	-$143.44M	-$2.67	N/A

Pharvaris has a beta of -2.34, suggesting that its stock price is 334% less volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market.

In the previous week, Pharvaris had 7 more articles in the media than Upstream Bio. MarketBeat recorded 12 mentions for Pharvaris and 5 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 1.31 beat Pharvaris' score of 0.58 indicating that Upstream Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	1 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Upstream Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Upstream Bio beats Pharvaris on 9 of the 13 factors compared between the two stocks.

How does Upstream Bio compare to Capricor Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Capricor Therapeutics has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Upstream Bio's return on equity of -41.73% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-69.50%	-55.81%
Upstream Bio	-4,718.96%	-41.73%	-40.35%

Capricor Therapeutics has higher revenue and earnings than Upstream Bio. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	77.42	-$105.04M	-$2.32	N/A
Upstream Bio	$2.85M	167.84	-$143.44M	-$2.67	N/A

Capricor Therapeutics has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market.

Capricor Therapeutics currently has a consensus target price of $48.36, indicating a potential upside of 62.24%. Upstream Bio has a consensus target price of $38.75, indicating a potential upside of 340.84%. Given Upstream Bio's higher probable upside, analysts clearly believe Upstream Bio is more favorable than Capricor Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Upstream Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Capricor Therapeutics had 15 more articles in the media than Upstream Bio. MarketBeat recorded 20 mentions for Capricor Therapeutics and 5 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 1.31 beat Capricor Therapeutics' score of 0.07 indicating that Upstream Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral
Upstream Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

21.7% of Capricor Therapeutics shares are owned by institutional investors. 9.2% of Capricor Therapeutics shares are owned by insiders. Comparatively, 13.6% of Upstream Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Capricor Therapeutics and Upstream Bio tied by winning 8 of the 16 factors compared between the two stocks.

How does Upstream Bio compare to Taysha Gene Therapies?

Taysha Gene Therapies (NASDAQ:TSHA) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Taysha Gene Therapies has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Upstream Bio's return on equity of -41.73% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.07%	-40.16%
Upstream Bio	-4,718.96%	-41.73%	-40.35%

Taysha Gene Therapies has higher revenue and earnings than Upstream Bio. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	185.30	-$109M	-$0.38	N/A
Upstream Bio	$2.85M	167.84	-$143.44M	-$2.67	N/A

Taysha Gene Therapies has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market.

Taysha Gene Therapies currently has a consensus target price of $11.64, indicating a potential upside of 84.70%. Upstream Bio has a consensus target price of $38.75, indicating a potential upside of 340.84%. Given Upstream Bio's higher probable upside, analysts clearly believe Upstream Bio is more favorable than Taysha Gene Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Upstream Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Taysha Gene Therapies had 3 more articles in the media than Upstream Bio. MarketBeat recorded 8 mentions for Taysha Gene Therapies and 5 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 1.31 beat Taysha Gene Therapies' score of 0.61 indicating that Upstream Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Upstream Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

77.7% of Taysha Gene Therapies shares are held by institutional investors. 3.8% of Taysha Gene Therapies shares are held by company insiders. Comparatively, 13.6% of Upstream Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Taysha Gene Therapies beats Upstream Bio on 11 of the 17 factors compared between the two stocks.

Get Upstream Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UPB vs. The Competition

Export

Metric	Upstream Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$509.37M	$3.42B	$6.34B	$12.37B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-3.02	18.47	20.66	25.63
Price / Sales	167.84	294.84	547.02	76.59
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	1.40	6.93	9.93	6.97
Net Income	-$143.44M	$24.11M	$3.55B	$333.62M
7 Day Performance	-3.30%	5.89%	1.69%	1.09%
1 Month Performance	-11.03%	-0.91%	0.48%	3.08%
1 Year Performance	0.11%	74.58%	39.38%	35.68%

Upstream Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UPB Upstream Bio	2.4106 of 5 stars	$8.79 -6.1%	$38.75 +340.8%	+2.7%	$509.37M	$2.85M	N/A	38	Positive News Earnings Report Analyst Forecast
ZYME Zymeworks	3.1793 of 5 stars	$26.68 -0.4%	$37.89 +42.0%	N/A	$1.98B	$105.96M	N/A	460	Trending News Buyback Announcement Analyst Revision
GENB Generate Biomedicines	N/A	$15.42 +6.6%	$23.20 +50.5%	N/A	$1.97B	$31.89M	N/A	312	Analyst Forecast Analyst Revision
PHVS Pharvaris	3.8768 of 5 stars	$30.02 flat	$42.73 +42.3%	+91.0%	$1.96B	N/A	N/A	30	Earnings Report Analyst Forecast
CAPR Capricor Therapeutics	2.4406 of 5 stars	$32.96 -1.6%	$46.09 +39.8%	+288.7%	$1.94B	$22.27M	N/A	101	Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UPB) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Upstream Bio (UPB) Competitors

UPB vs. ZYME, GENB, PHVS, CAPR, and TSHA

How does Upstream Bio compare to Zymeworks?

Summary

How does Upstream Bio compare to Generate Biomedicines?

Summary

How does Upstream Bio compare to Pharvaris?

Summary

How does Upstream Bio compare to Capricor Therapeutics?

Summary

How does Upstream Bio compare to Taysha Gene Therapies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPB vs. The Competition

Upstream Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Upstream Bio (UPB) Competitors

UPB vs. ZYME, GENB, PHVS, CAPR, and TSHA

How does Upstream Bio compare to Zymeworks?

Which has more risk & volatility, ZYME or UPB?

Which has stronger valuation & earnings, ZYME or UPB?

Do institutionals & insiders believe in ZYME or UPB?

Does the media prefer ZYME or UPB?

Do analysts prefer ZYME or UPB?

Is ZYME or UPB more profitable?

Summary

How does Upstream Bio compare to Generate Biomedicines?

Is GENB or UPB more profitable?

Which has preferable earnings & valuation, GENB or UPB?

Does the media favor GENB or UPB?

Do analysts prefer GENB or UPB?

Summary

How does Upstream Bio compare to Pharvaris?

Is PHVS or UPB more profitable?

Do analysts prefer PHVS or UPB?

Which has preferable earnings & valuation, PHVS or UPB?

Which has more risk and volatility, PHVS or UPB?

Does the media favor PHVS or UPB?

Summary

How does Upstream Bio compare to Capricor Therapeutics?

Is CAPR or UPB more profitable?

Which has stronger valuation and earnings, CAPR or UPB?

Which has more risk and volatility, CAPR or UPB?

Do analysts prefer CAPR or UPB?

Does the media refer more to CAPR or UPB?

Do insiders & institutionals believe in CAPR or UPB?

Summary

How does Upstream Bio compare to Taysha Gene Therapies?

Is TSHA or UPB more profitable?

Which has higher valuation & earnings, TSHA or UPB?

Which has more volatility & risk, TSHA or UPB?

Do analysts prefer TSHA or UPB?

Does the media prefer TSHA or UPB?

Do institutionals & insiders believe in TSHA or UPB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPB vs. The Competition

Upstream Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools